🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 14% of ingredients have research evidence
B Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Tablet(s) Serving Size
30 Servings
Other Combinations Product Type
14% Evidence Coverage

Supplement Facts — Evidence Check

20 mg (100% DV)
✅ 1.4× RDA — within safe limits 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 20mg UL 35mg
Guggulipid
1000 mg
Red Rice Extract
700 mg
Beta-Sitosterol
300 mg
Beta Glucan
50 mg
Policosanol
3 mg

Other Ingredients

Dicalcium Phosphate Cellulose Croscarmellose Sodium Stearic Acid Silicon Dioxide Magnesium Stearate Pharmaceutical Glaze

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Use: Adults - Take 2 tablets daily before meals, one in the morning and one in the evening as a food supplement.

⚠️ Warnings & Precautions

Caution: Do not exceed recommended dose.

Pregnant or nursing mothers, children under 18 and individuals with a known medical condition should consult a physician before using this or any dietary supplement.

Pregnant or nursing mothers, children under 18 and individuals with a known medical condition should consult a physician before using this or any dietary supplement. Keep out of reach of children.

Do not use if safety seal is damaged or missing.

Allergen Warning: Contains soy (beta-sitosterol)

🧪 Formulation Notes

Contains beta-sitosterol and guggul lipids

All natural formula with beta-sitosterol and guggul lipids

Allergen Warning: Contains soy (beta-sitosterol)

Additional Information

All-natural ingredients

Store in a cool, dry place.

SKU: CHOLCARE v5.4

Made in USA

Cholesterol support formula

v5.4

Product Details

UPC / SKU 8 50004 00102 8
DSLD Entry Date 2017-03-24
Product Type Other Combinations
Form Tablet or Pill
DSLD ID 71943
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →